Monitoring plasma antibiotic concentrations in Spanish hospitals;Monitorización de concentraciones plasmáticas de antibióticos en hospitales españoles

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 1, 2006, Pages 14-19

  Álvarez Lerma, Francisco ^a   Grau, Santiago ^a   Marín Casino, Mónica ^a   Olaechea, Pedro ^b   Sánchez, Miguel ^c   Martín, Estrella ^d   Pujol, Miquel ^e  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL DE GALDAKAO   (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^d HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Critically ill patients; Monitoring antibiotics; Plasma antibiotic concentrations

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; GENTAMICIN; VANCOMYCIN;

CLINICAL PRACTICE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG MONITORING; GENERAL HOSPITAL; HEALTH SURVEY; HOSPITAL SERVICE; HUMAN; MEDICAL RECORD; REVIEW;

EID: 33344459553     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13083369     Document Type: Article

References (14)

1. Sádaba B, Azanza JR. Farmacocinética en situaciones especiales (geriatría, recién nacidos, y niños, embarazo y puerperio). En: García Sánchez JE, López R, Prieto J, editores. Sociedad Española de Quimioterapia. Antimicrobianos en Medicina. Barcelona: Prous Science; 1999. p. 121-31.
2. Blondeu JM, Hansen G, Metzler K, Hedlin P. The role of PK/PD parameters to avoid and increase of resistance: mutant prevention concentration. J Chemother. 2004;16 Suppl 3:1-19.
3. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279:159-60.
4. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham M, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073-81.
5. Highet VS, Forrest A, Ballow CH, Schentag JJ. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J Antimicrob Chemother. 1999;43 Suppl A:53-63.
6. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodinamics in the selection of antibiotics for respiratory tract infections. J Chemother. 1997;9 Suppl 3:38-44.
7. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH. Pharmacodynamic evaluation of factors associated with development of bacteria resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998;42:521-7.
8. Álvarez Lerma F, Palomar M, Grau S. Management of antimicrobial use in the intensive care unit. Drugs. 2001;61:763-5.
9. Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet. 2001;40:833-68.
10. Pea F, Porreca L, Baraldo M, Furlanut M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother. 2000;45:329-35.
11. Catálogo Nacional de Hospitales. Instituto de Información Sanitaria. (Fecha de consulta 9 de mayo de 2005.) Disponible en: http://www.msc.es/Diseno/sns/sns_sistemas_informacion.htm
12. Martínez H, Castera E, Catalá RM, Cobos FJ, Sacristán MP, Sora M. Grupo de Estudios de Utilización de Medicamentos de la Sociedad Española de Farmacia Hospitalaria. Utilización de antiinfecciosos en los hospitales españoles: evolución 1997-1999. Farm Hosp. 2001;25:3-12.
13. Hatala R, Dinh T, Cook DJ. Once-Daily Aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 1996;124:717-25.
14. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Laboratory Reference Values. N Engl J Med. 2004;351:1548-63.